sponsored
PatientsVille.com Logo

PatientsVille

Sutent Medical Research Studies

Up-to-date List of Sutent Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Sutent Medical Research Studies

Rank Status Study
1 Recruiting Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
Condition: Urinary Tract Urothelial Carcinoma
Intervention: Drug: Sunitinib
Outcome Measures: Determine complete response rate at 3 months in patient with high risk non-invasive urothelial carcinoma of the lower urinary tract treated with a intravesical BCG followed by sunitinib;   Determine complete response percentage of study regimen at 6 months.;   Assess recurrence-free survival at 2 years in patients with intact bladder.;   Determine toxicity related to treatment with BCG followed by Sunitinib.
2 Recruiting Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
Conditions: Papillary Thyroid Cancer;   Follicular Thyroid Cancer;   Differentiated Thyroid Cancer
Intervention: Drug: SU011248, Sutent
Outcome Measures: The primary objective is to assess clinical benefit rate, defined as complete response, partial response, or stable disease per RECIST criteria.;   The secondary objective will be to assess the safety of Sutent in this patient population.
3 Not yet recruiting CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Crixotinib 200 mg and Sunitinib Cohort 1;   Drug: Crixotinib 250 mg and Sunitinib Cohort 2;   Drug: Crizotinib & Sunitinib 37.5 mg Cohort 3
Outcome Measures: Maximum tolerated dose of the treatment drugs in the patients that are taking it.;   Changes that occur in tumor tissue before treatment and after treatment.;   Laboratory results to make sure the treatment is safe.
4 Unknown  Capiri-Sutent Phase-1 in Advanced Colo-rectal Cancer
Condition: Colorectal Cancer
Intervention: Drug: capiri-Sutent
Outcome Measures: Maximum Tolerated Dose;   determine the safety and toxicity profile using the CTCAE criteria.
5 Recruiting Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma
Condition: Soft Tissue Sarcoma
Interventions: Drug: Sunitinib malate;   Radiation: Radiotherapy
Outcome Measures: To determine the maximum dose of sunitinib at which the combination of sunitinib and radiotherapy pre-operatively is safe and tolerable.;   To estimate response rates for the combination of sunitinib and radiotherapy.
6 Recruiting Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule
Condition: Clear Cell, Metastatic Renal Cell Carcinoma
Intervention: Drug: Sunitinib
Outcome Measures: Progression free survival for sunitinib given on an individualized dose/schedule;   Patient tolerability and safety of an individualized dose/schedule;   Dose intensity of sunitinib given on an individualized dose/schedule.;   Overall survival and patient quality of life
7 Recruiting A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: sunitinib malate dose escalation;   Drug: sunitinib malate
Outcome Measures: Pharmacokinetics- Estimated steady-state maximum plasma concentration (Cmax) for sunitinib and its active metabolite SU012662;   Pharmacokinetics- estimated area under the plasma concentration versus time curve from time zero to 24 hours post dose (AUC24) for sunitinib and its active metabolite SU012662;   Pharmacokinetics- estimated oral clearance (CL/F) for sunitinib;   Pharmacokinetics- Observed single-dose maximum plasma concentration (Cmax) for sunitinib and its active metabolite SU012662;   Pharmacokinetics- Observed time to Cmax (tmax) for sunitinib and its active metabolite SU012662;   Pharmacokinetics- Observed area under the plasma concentration versus time curve from time zero to 8 hours post dose (AUC8) for sunitinib and its active metabolite SU012662;   Objective response rate;   Duration of response;   Progression-free survival;   Overall survival at 2 years after study enrollment;   Estimated sunitinib plasma concentration at which 50% of the maximum effect for each selected efficacy parameter (eg, sum of largest diameters for target tumors) is observed;   Estimated sunitinib plasma concentration at which 50% of the maximum effect for each selected safety endpoint (eg, absolute neutrophil count) is observed
8 Unknown  Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Intervention: Drug: Sunitinib
Outcome Measures: To evaluate the dose limiting toxicity and maximal tolerated dose of sunitinib given concurrently with irradiation as neoadjuvant treatment in soft tissue sarcoma.;   To evaluate the response to sunitinib given concurrently with radiation as neoadjuvant treatment in soft tissue sarcoma.
9 Recruiting Study Evaluating Two Loading Regimens of Sunitinib Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: 12.5mg sunitinib with Cisplatin and Gemcitabine;   Drug: 25mg Sunitinib alternating with Cisplatin and Gemcitabine
Outcome Measure: Clinical Response
10 Not yet recruiting Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
Conditions: Genitourinary Cancer;   Kidney Cancer
Interventions: Drug: Sunitinib;   Behavioral: Questionnaire
Outcome Measures: Rate of Toxicity;   Progression-Free Survival (PFS)
11 Recruiting Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Conditions: Paraganglioma;   Pheochromocytoma
Intervention: Drug: Sunitinib
Outcome Measures: Clinical benefit rate (CBR) which is defined as either a partial response (PR) complete response (CR) or stable disease (SD) for ≥ 12 weeks measured using Response Evaluation Criteria in Solid Tumors (RECIST) criteria.;   Biochemical response of > 20% drop in; 24-hour urinary metanephrines, catecholamines or serum chromogranin A, sustained for > 12-week period;   Overall survival;   Time to progression;   Overall response rate (PR) + (CR)
12 Unknown  A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
Condition: Metastatic Uveal Melanoma
Interventions: Drug: Dacarbazine;   Drug: Sunitinib
Outcome Measures: Progression Free Survival;   Overall Survival;   Overall Response Rate;   Time to progression on first-line treatment compared to second-line treatment;   Overall response rate on first-line treatment compared to overall response rate on second-line treatment for patients who receive cross-over therapy;   Assessment of Adverse Events
13 Unknown  Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Conditions: Non Small-cell Lung Cancer;   Renal-cell Cancer;   Gastrointestinal Stroma Tumor
Interventions: Drug: Sunitinib;   Drug: Erlotinib;   Drug: Midazolam;   Drug: Caffeine
Outcome Measures: Steady-state partial area-under the plasma concentration-time curve over 24 hours (AUC24h) of sunitinib and erlotinib and CYP3A4/1A2-phenotype activity as defined in the protocol;   Sunitinib and Erlotinib-associated toxicity according to the CTC criteria (v.3.0);   Concentrations of Sunitinib, Erlotinib and probe drugs (Midazolam, Caffeine) in whole blood, sampled from patient's dried blood spots (DBS)
14 Unknown  Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors
Condition: Malignant Solid Tumour
Intervention: Drug: Sunitinib
Outcome Measures: Number of Participants with Adverse Events as a Measure of Safety and Tolerability;   objective response rate;   time to tumor progression;   validating the associations between genetic markers;   tumor biopsy and peripheral blood sample for DNA sequencing;   Progression free survival
15 Recruiting Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.
Condition: Solid Tumors
Intervention: Drug: Sunitinib
Outcome Measures: maximum tolerated dose (MTD) of sunitinib;   Number of participants with serious and non-serious adverse events;   Calculation of maximum plasma drug concentration, sunitinib half life, Area Under the Concentration-Time Curve (AUC 0-48h), clearance and volume of distribution;   Time to Disease Progression;   Recommended phase II dose (RP2D) and the optimal dose schedule;   Measurement of intratumoral and skin concentration of sunitinib
16 Unknown  Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)
Conditions: Clear Cell Renal Cell Carcinoma;   Metastasis
Intervention: Drug: Sunitinib
Outcome Measures: Response rate of primary tumor based on Response Evaluation Criteria In Solid Tumors (RECIST) criteria;   Overall survival rate after Sunitinib therapy;   Pathologic evaluation after Sunitinib therapy;   Quality of life (QoL) assessed by EORTC QLQ-C30 questionnaire (Korean version);   Resectability based on R0 resection rate
17 Unknown  Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy
Condition: Carcinoma Renal Cells
Intervention: Drug: Sunitinib
Outcome Measures: Progression-free survival;   Global survival;   Response global;   Duration of response;   Security and tolerability of Sunitinib
18 Recruiting Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
Conditions: Ovarian Cancer;   Adverse Effects
Intervention: Drug: Sunitinib
Outcome Measure: Response rate
19 Recruiting A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma
Condition: Unresectable and Advanced Cholangiocarcinoma
Intervention: Drug: Sunitinib
Outcome Measures: Overall survival;   To evaluate the criteria of efficacy (PFS, ORR);   To evaluate the effects of sunitinib on tumor angiogenesis;   To characterize the safety profile of sunitinib (collection of AEs);   To identify markers associated with response to sunitinib
20 Recruiting Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib;   Drug: Everolimus
Outcome Measures: Progression-free survival (PFS) rate 1 year;   PFS of rotational arm versus PFS of the 2 lines in control arm;   Overall Survival;   Safety Profile;   Objective tumor response rate per arm

These studies may lead to new treatments and are adding insight into Sutent etiology and treatment.

A major focus of Sutent research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Sutent